EOLS
$4.91
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
Recent News
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Evolus (NASDAQ:EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers amid changing consumer sentiment. Speaking at the Leerink Conference, CEO Dav
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance
Evolus has seen its fair value estimate adjusted slightly, with the price target moving from US$15.17 to US$14.67 per share. Analysts are tying this trim to the company’s preliminary 2025 net revenues landing at the low end of expectations and a cautious tone in 2026 guidance. This has led to a reset in long term outlooks and mixed reactions across the Street. As you read on, you will see how to track these shifting views and what to watch as the Evolus story develops. Stay updated as the...
Why Evolus Stock Soared Today
The promise of a more youthful appearance is a powerful draw.
Evolus, Inc. Q4 2025 Earnings Call Summary
Moby summary of Evolus, Inc.'s Q4 2025 earnings call
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
Evolus Inc (EOLS) reports a 14% increase in fourth-quarter revenue, driven by Jeuveau's market share gains and international expansion.